A detailed history of Eagle Bay Advisors LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Eagle Bay Advisors LLC holds 54 shares of VRTX stock, worth $25,221. This represents 0.01% of its overall portfolio holdings.

Number of Shares
54
Previous 54 -0.0%
Holding current value
$25,221
Previous $25,000 -0.0%
% of portfolio
0.01%
Previous 0.02%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 08, 2024

BUY
$407.69 - $446.08 $9,376 - $10,259
23 Added 74.19%
54 $22,000
Q2 2022

Aug 19, 2022

BUY
$234.96 - $292.55 $7,283 - $9,069
31 New
31 $8.74 Million
Q1 2022

May 11, 2022

SELL
$221.42 - $260.97 $221 - $260
-1 Closed
0 $0
Q4 2021

Jan 21, 2022

SELL
$177.01 - $223.45 $9,027 - $11,395
-51 Reduced 98.08%
1 $1,000
Q2 2021

Jul 30, 2021

BUY
$187.49 - $221.1 $9,749 - $11,497
52 New
52 $12,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $120B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Eagle Bay Advisors LLC Portfolio

Follow Eagle Bay Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Eagle Bay Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Eagle Bay Advisors LLC with notifications on news.